23-valent pneumococcal polysaccharide vaccine

Generic Name: 23-valent pneumococcal polysaccharide vaccine

Clinical Trials

Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine

Phase 1

Conditions: Pneumococcal Vaccines

Interventions: Biological: 26-Valent pneumococcal conjugate vaccine
Biological: 13-Valent pneumococcal conjugate vaccine
Biological: 23-Valent pneumococcal polysaccharide vaccine

First Posted Date: 2024-11-25

Last Posted Date: 2025-01-27

Lead Sponsor: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd

Target Recruit Count: 450

Registration Number: NCT06703203

Locations: 🇨🇳
Henan Provincial Center for Disease Control and Prevention, Shangqiu, Henan, China

Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine

Phase 2

Recruiting

Conditions: Pneumococcal Infectious Disease

Interventions: Biological: Reinovax PCV24 formulation 1
Biological: Reinovax PCV24 formulation 2
Biological: Reinovax PCV24 formulation 3
Biological: PPSV23

First Posted Date: 2024-11-07

Last Posted Date: 2024-11-27

Lead Sponsor: Shanghai Reinovax Biologics Co.,LTD

Target Recruit Count: 992

Registration Number: NCT06678620

Locations: 🇨🇳
Pizhou Center for Disease Control and Prevention, Pizhou, Jiangsu, China
🇨🇳
Xuzhou Center for Disease Control and Prevention, Xuzhou, Jiangsu, China

Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older

Phase 1

Completed

Conditions: Pneumococcal Infectious Disease

Interventions: Biological: Reinovax PCV24 formulation 1
Biological: Reinovax PCV24 formulation 2
Biological: PPSV23
Biological: Placebo

First Posted Date: 2024-11-07

Last Posted Date: 2024-11-07

Lead Sponsor: Shanghai Reinovax Biologics Co.,LTD

Target Recruit Count: 240

Registration Number: NCT06678607

Locations: 🇨🇳
Zhenjiang Center for Disease Control and Prevention, Zhenjiang, Jiangsu, China

Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans

Phase 4

Not yet recruiting

Conditions: Immunosuppression
Pneumococcal Vaccines

Interventions: Drug: 15-valent pneumococcal conjugate vaccine
Drug: 23-valent pneumococcal polysaccharide vaccine

First Posted Date: 2024-02-22

Last Posted Date: 2024-02-22

Lead Sponsor: VA Sierra Nevada Health Care System

Target Recruit Count: 45

Registration Number: NCT06271681

A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)

Phase 3

Completed

Conditions: Pneumococcal Infection

Interventions: Biological: V116
Biological: PPSV23

First Posted Date: 2023-12-20

Last Posted Date: 2025-03-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 882

Registration Number: NCT06177912

Locations: 🇨🇦
Premier Clinical Trial Network ( Site 0008), Hamilton, Ontario, Canada
🇺🇸
Central Research Associates ( Site 0145), Birmingham, Alabama, United States
🇺🇸
Velocity Clinical Research, Phoenix ( Site 0122), Phoenix, Arizona, United States

and more 89 locations

Extension Safety and Immunogenicity Study of GPNV-001

Phase 1

Completed

Conditions: Pneumococcal Infections

Interventions: Biological: Gamma-PN3
Biological: Prevenar-13
Biological: Pneumovax-23
Biological: Placebo

First Posted Date: 2023-08-08

Last Posted Date: 2024-12-18

Lead Sponsor: GPN Vaccines

Target Recruit Count: 60

Registration Number: NCT05982314

Locations: 🇦🇺
University of Adelaide, Adelaide, South Australia, Australia

A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nipocalimab
Biological: Tdap
Biological: PPSV23

First Posted Date: 2023-04-25

Last Posted Date: 2025-03-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 32

Registration Number: NCT05827874

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above

Phase 1

Completed

Conditions: Pneumonia

Interventions: Biological: 23-valent pneumococcal polysaccharide vaccine
Biological: pneumococcal vaccine polyvalent

First Posted Date: 2023-04-18

Last Posted Date: 2024-10-16

Lead Sponsor: Ab&b Biotechnology Co., Ltd.JS

Target Recruit Count: 144

Registration Number: NCT05815264

Locations: 🇨🇳
Qi County Center for Disease Control and Prevention, Hebi, Henan, China

Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)

Phase 3

Completed

Conditions: Pneumococcal Infection

Interventions: Biological: V116
Biological: PCV15
Biological: Placebo
Biological: PPSV23

First Posted Date: 2023-01-25

Last Posted Date: 2025-02-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 518

Registration Number: NCT05696080

Locations: 🇨🇱
Centro de Investigación del Maule-Centro de Investigación 2 ( Site 1010), Talca, Maule, Chile
🇨🇦
Clinique de médecine Urbaine du Quartier Latin ( Site 0111), Montreal, Quebec, Canada
🇺🇸
Mid Hudson Medical Research ( Site 0008), New Windsor, New York, United States

and more 41 locations

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.

Phase 1

Recruiting

Conditions: Pneumococcal Infections

Interventions: Biological: Gamma-PN3
Drug: Placebo
Biological: Prevenar-13
Biological: Pneumovax-23

First Posted Date: 2022-12-29

Last Posted Date: 2023-02-23

Lead Sponsor: GPN Vaccines

Target Recruit Count: 117

Registration Number: NCT05667740

Locations: 🇦🇺
CMAX, Adelaide, South Australia, Australia

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy